Jotbody
Jotbody (HK) Limited, founded in 2020 and based in Hong Kong, is a cutting-edge biotechnology company specializing in nanobody discovery and extracellular vesicle (EV) research. The company offers a comprehensive suite of services including nanobody discovery, humanization, bioconjugation, multispecific nanobody development, AI optimization, and Fc-fusion nanobody development, alongside EV isolation, purification, characterization, omics, functionalization, and CDMO solutions. Jotbody's business model centers on providing high-quality nanobody discovery services, research reagents, and innovative EV solutions to the global scientific community, serving customers in over 30 countries. Their proprietary technology platforms enable rapid delivery of tailored nanobody sequences with independent intellectual property rights for clients. The company has demonstrated strong traction with 200+ publications and 5000+ citations, and has been recognized by Forbes Asia as one of the "100 Companies to Watch in 2023." Strategic collaborations with academic and industry partners, including work on therapeutic EV applications in cancer and other diseases, further position Jotbody as a leader in life science innovation. Key products include nanobody reagents, EV reagents, and novel membrane labeling dyes (JotDyes) for EV research, as well as kits for EV transfection and surface modification.
Jotbody
Jotbody (HK) Limited, founded in 2020 and based in Hong Kong, is a cutting-edge biotechnology company specializing in nanobody discovery and extracellular vesicle (EV) research. The company offers a comprehensive suite of services including nanobody discovery, humanization, bioconjugation, multispecific nanobody development, AI optimization, and Fc-fusion nanobody development, alongside EV isolation, purification, characterization, omics, functionalization, and CDMO solutions. Jotbody's business model centers on providing high-quality nanobody discovery services, research reagents, and innovative EV solutions to the global scientific community, serving customers in over 30 countries. Their proprietary technology platforms enable rapid delivery of tailored nanobody sequences with independent intellectual property rights for clients. The company has demonstrated strong traction with 200+ publications and 5000+ citations, and has been recognized by Forbes Asia as one of the "100 Companies to Watch in 2023." Strategic collaborations with academic and industry partners, including work on therapeutic EV applications in cancer and other diseases, further position Jotbody as a leader in life science innovation. Key products include nanobody reagents, EV reagents, and novel membrane labeling dyes (JotDyes) for EV research, as well as kits for EV transfection and surface modification.